GlobalRPh Renal Dosing Masterv6.6
GlobalRPh source record

Allopurinol

Local official-label summaryBase record retrieved 2026-09-05See the evidence for this drug4 sources available - open source summaries, references and comparisons
READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Cautions / source differences (2)
Review first - source-specific qualification

Before use: Allopurinol

Gout initiation and cancer-associated hyperuricemia have different renal tables in the same label. The dialysis schedule belongs to the cancer indication, not a universal gout regimen.

Before applying: Select the indication first. An initial low gout dose is not an eGFR-specific maintenance ceiling.

Evidence for this qualification

Source-specific interpretation; independent clinician adjudication pending.

Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.

Choose a source to read (4)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

1 additional source qualifications - review before use
Starting dose, maintenance dose and indication must remain separate

Retained GlobalRPh text includes older CrCl-based ceilings. The retrieved RX gout table specifies lower initiation doses without band-specific maxima; the 2020 ACR guideline supports monitored titration to target, including in CKD.

Before applying: Do not silently blend old ceilings, new starting doses or cancer-therapy dialysis rows. Reconcile the intended gout regimen, source date and renal measure with a clinician.

Also check: Starting dose, maintenance dose and indication must remain separate

Official source

Allopurinol tablets - Aurobindo indication-specific renal tables

Product / population
Adults; gout initiation versus cancer-therapy hyperuricemia, not interchangeable indications.
Renal measure
Label prints eGFR in mL/min without a surface-area suffix; do not silently convert to CrCl.

Renal guidance and important limits

Limits that apply to these rows

For impaired-renal gout, increase by 50 mg/day every 2-4 weeks to urate response; an eGFR-specific maximum is not defined.

Renal dosing for recurrent calcium oxalate stones is not established. Pediatric renal instructions are not inferred. Review hypersensitivity, kidney function and interactions.

Allopurinol oral - adult GOUT initial dosing
eGFR (source prints mL/min)Source-specific instruction
>60No renal modification to initial dosing
>30 to 6050 mg daily
>15 to 3050 mg every other day
5-1550 mg twice weekly
<550 mg weekly
Allopurinol oral - adult CANCER-associated hyperuricemia
eGFR (source prints mL/min)Source-specific instruction
>20 to 60No dose modification in this table
10-20200 mg/day
<10100 mg/day
Dialysis guidance - separate source-specific schedules
Allopurinol oral - CANCER indication dialysis
SettingSource-specific instruction
On dialysis50 mg every 12 hours OR 100 mg every 24 hours
Read the retained text before reformatting

Allopurinol oral - adult GOUT initial dosing

eGFR (source prints mL/min)Source-specific instruction
>60No renal modification to initial dosing
>30 to 6050 mg daily
>15 to 3050 mg every other day
5-1550 mg twice weekly
<550 mg weekly

Allopurinol oral - adult CANCER-associated hyperuricemia

eGFR (source prints mL/min)Source-specific instruction
>20 to 60No dose modification in this table
10-20200 mg/day
<10100 mg/day

Allopurinol oral - CANCER indication dialysis

SettingSource-specific instruction
On dialysis50 mg every 12 hours OR 100 mg every 24 hours

For impaired-renal gout, increase by 50 mg/day every 2-4 weeks to urate response; an eGFR-specific maximum is not defined.

Renal dosing for recurrent calcium oxalate stones is not established. Pediatric renal instructions are not inferred. Review hypersensitivity, kidney function and interactions.

Source revision: 5/2024 | Retrieved: 2026-09-10. Retrieval date is not the revision date.

Source: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=311ca755-c022-4251-97eb-dd9be86a993f

Scope: Selected source sections stored locally. Not a complete monograph or independent clinical approval. GlobalRPh v6.6.

Full source card / provenance

Other formulations / related references (1)

Confirm the exact product. These links do not imply interchangeable doses or indications.

Allopurinol - ALOPRIM intravenous infusionRelated reference only; not an interchangeable dose or indication.
All sources, comparison tools and evidence navigation
Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Read 2 source difference / applicability notes

Preserved GlobalRPh source

Preserved original GlobalRPh source

Preserved historical content; not revalidated as current prescribing guidance.

Renal method: Read the measure and population stated in the original source sections.
Retrieved: 2026-09-05

Read local renal resultOpen original reference
Official product label

Allopurinol tablets - Aurobindo indication-specific renal tables

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.
Before using this finding

Select the indication first. An initial low gout dose is not an eGFR-specific maintenance ceiling.

Adults; gout initiation versus cancer-therapy hyperuricemia, not interchangeable indications.

Renal method: Label prints eGFR in mL/min without a surface-area suffix; do not silently convert to CrCl.
Retrieved: 2026-09-10

Read local renal resultOpen original reference
GlobalRPh RX List

GlobalRPh RX List - ZYLOPRIM

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Oral allopurinol; this source distinguishes gout initiation from cancer-therapy hyperuricemia. It is not an IV ALOPRIM regimen.

Renal method: eGFR, mL/min as printed, for gout initiation; separate cancer table uses CrCl
Retrieved: 2026-09-09

Read local renal resultOpen original reference
Professional guidance

2020 ACR gout guideline - initiation versus titrated maintenance

Professional guidance with defined scope. Publication date, institutional setting and source limitations remain controlling. This is not automatic preference over another source.

2020 ACR gout guideline; urate-lowering treatment selection and titration, not cancer-therapy or dialysis-specific dosing.

Renal method: CKD stage and serial serum urate; not a numerical CrCl dosing table
Retrieved: 2026-09-09

Read local renal resultOpen original reference

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Product / population check

Confirm the exact formulation before using a renal source

These links compare product identities, not interchangeable doses. A selected summary is not a complete prescribing monograph.

Source-specific review points

Starting dose, maintenance dose and indication must remain separateBefore use: Allopurinol

Read the attributed comparison notes and source cards below. No conflict has been silently adjudicated.

Source-quality holds
Find text within this drug
Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. Searches stay on this page and are not saved or sent.

All source summaries, original wording and provenance
Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources
Jump to renal guidanceRead 2 difference / caution notesClinician guide

Select two distinct source versions. The complete stored summaries will appear below.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Read before choosing a regimen

Source differences and product cautions

Search differences across all drugs

These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.

legacy source versus titrated maintenance

Starting dose, maintenance dose and indication must remain separate

Retained GlobalRPh text includes older CrCl-based ceilings. The retrieved RX gout table specifies lower initiation doses without band-specific maxima; the 2020 ACR guideline supports monitored titration to target, including in CKD.

How to use this: Do not silently blend old ceilings, new starting doses or cancer-therapy dialysis rows. Reconcile the intended gout regimen, source date and renal measure with a clinician.

GlobalRPh RX List - ZYLOPRIM2020 ACR gout guideline - initiation versus titrated maintenancePreserved original GlobalRPh contentAllopurinol - ALOPRIM intravenous infusion

Source-specific interpretation; independent clinician adjudication pending.

source scope and renal guidance

Before use: Allopurinol

Gout initiation and cancer-associated hyperuricemia have different renal tables in the same label. The dialysis schedule belongs to the cancer indication, not a universal gout regimen.

How to use this: Select the indication first. An initial low gout dose is not an eGFR-specific maintenance ceiling.

Allopurinol tablets - Aurobindo indication-specific renal tables

Source-specific interpretation; independent clinician adjudication pending.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

New source summary - independent clinical review pending. Summaries of the identified label sections are included locally. Source import and numeric transcription checks are not independent two-reference validation. Do not treat this card as an approved institutional dosing protocol.

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scopeAllopurinol tablets - Aurobindo indication-specific renal tablesGlobalRPh RX List - ZYLOPRIM2020 ACR gout guideline - initiation versus titrated maintenance
Choose two source checkboxes below.
Historical source content is not a current prescription. Original GlobalRPh recommendations are preserved, not automatically certified as current. Product-label and professional additions below are separately attributed. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
Locally stored source content

Original GlobalRPh protocol

Clinical facts and comments transcribed into a structured reading format. This is not a byte-for-byte HTML archive. Original source: https://globalrph.com/renal/allopurinol/

Usual Dosing (Adults)

Gout: initially 100mg once daily. Increase by 100mg/day every 2 to 4 weeks - titrated to desired uric acid level (~ <6 mg/dL). Usual range:

(Mild gout): 200-300mg/day.

Moderate-severe: 400-600mg/day.

Maximum dose/day: 800mg

GRPH-allopurinol-01 · Source section: Usual Dosing (Adults)Renal section finder

Renal Dosing

Since allopurinol and its metabolites are primarily eliminated only by the kidney, accumulation of the drug can occur in renal failure, and the dose of allopurinol tablets USP should consequently be reduced. With a creatinine clearance of 10 to 20 mL/min, a daily dosage of 200 mg of allopurinol tablet USP is suitable. When the creatinine clearance is less than 10 mL/min, the daily dosage should not exceed 100 mg.

With extreme renal impairment (creatinine clearance less than 3 mL/min) the interval between doses may also need to be lengthened.

Package insert summarized:

[10-20]: 200mg q24h.

[<10 mL/min]: Do not exceed 100mg/day.

[<3 ml/min]: Administer 100 mg at extended intervals.

[Titrate to desired uric acid level]

Severe impairment: In patients with severely impaired renal function or decreased urate clearance, the half-life of oxipurinol in the plasma is greatly prolonged. Therefore, a dose of 100 mg per day or 300 mg twice a week, or perhaps less, may be sufficient to maintain adequate xanthine oxidase inhibition to reduce serum urate levels.

GRPH-allopurinol-02 · Source section: Renal DosingRenal section finder

Hemodialysis

100mg q24-48h (give dose after dialysis on dialysis days.)

Titrate to desired uric acid level.

GRPH-allopurinol-03 · Source section: HemodialysisRenal section finder
Separate U.S. product-label layer

FDA / DailyMed dosing and renal information

Official

Allopurinol tablets - Aurobindo indication-specific renal tables

Open original reference

Open / share this exact local source

DailyMed / NLM exact product labeling · Adults; gout initiation versus cancer-therapy hyperuricemia, not interchangeable indications.

Renal method: Label prints eGFR in mL/min without a surface-area suffix; do not silently convert to CrCl.
Source date: 5/2024
Retrieved: 2026-09-10

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.
Before using this finding

Select the indication first. An initial low gout dose is not an eGFR-specific maintenance ceiling.

Selected source sections stored locally. Not a complete monograph or independent clinical approval.

Renal guidance and important limits

Limits that apply to these rows

For impaired-renal gout, increase by 50 mg/day every 2-4 weeks to urate response; an eGFR-specific maximum is not defined.

Renal dosing for recurrent calcium oxalate stones is not established. Pediatric renal instructions are not inferred. Review hypersensitivity, kidney function and interactions.

Allopurinol oral - adult GOUT initial dosing
eGFR (source prints mL/min)Source-specific instruction
>60No renal modification to initial dosing
>30 to 6050 mg daily
>15 to 3050 mg every other day
5-1550 mg twice weekly
<550 mg weekly
Allopurinol oral - adult CANCER-associated hyperuricemia
eGFR (source prints mL/min)Source-specific instruction
>20 to 60No dose modification in this table
10-20200 mg/day
<10100 mg/day
Dialysis guidance - separate source-specific schedules
Allopurinol oral - CANCER indication dialysis
SettingSource-specific instruction
On dialysis50 mg every 12 hours OR 100 mg every 24 hours
Read the retained text before reformatting

Allopurinol oral - adult GOUT initial dosing

eGFR (source prints mL/min)Source-specific instruction
>60No renal modification to initial dosing
>30 to 6050 mg daily
>15 to 3050 mg every other day
5-1550 mg twice weekly
<550 mg weekly

Allopurinol oral - adult CANCER-associated hyperuricemia

eGFR (source prints mL/min)Source-specific instruction
>20 to 60No dose modification in this table
10-20200 mg/day
<10100 mg/day

Allopurinol oral - CANCER indication dialysis

SettingSource-specific instruction
On dialysis50 mg every 12 hours OR 100 mg every 24 hours

For impaired-renal gout, increase by 50 mg/day every 2-4 weeks to urate response; an eGFR-specific maximum is not defined.

Renal dosing for recurrent calcium oxalate stones is not established. Pediatric renal instructions are not inferred. Review hypersensitivity, kidney function and interactions.

RDM64-official-allopurinol-aa4c5dd87e-C1 · Source locator: Section 2.6 Tables 1 and 2 with footnotes; sections 5 and 7.

Source-specific limits

For impaired-renal gout, increase by 50 mg/day every 2-4 weeks to urate response; an eGFR-specific maximum is not defined.

Renal dosing for recurrent calcium oxalate stones is not established. Pediatric renal instructions are not inferred. Review hypersensitivity, kidney function and interactions.

Source identity and provenance
Source family
product_label
Source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=311ca755-c022-4251-97eb-dd9be86a993f
Retrieved
2026-09-10
Exact label title
Allopurinol tablets - Aurobindo indication-specific renal tables
DailyMed Set ID
311ca755-c022-4251-97eb-dd9be86a993f
Label revision
5/2024
Renal-function method
Label prints eGFR in mL/min without a surface-area suffix; do not silently convert to CrCl.
Source date/version
5/2024
Hash meaning
Local authored summary, not source HTML/XML/PDF bytes
Local summary SHA-256
d90594f9228bc78a70693788b6ec9806464826dc92c80c7378ce398642f03e58
Locally imported selected renal sections

GlobalRPh RX List renal information

Rxlist

GlobalRPh RX List - ZYLOPRIM

Open original reference

Open / share this exact local source

GlobalRPh-hosted RX List · Oral allopurinol; this source distinguishes gout initiation from cancer-therapy hyperuricemia. It is not an IV ALOPRIM regimen.

Renal method: eGFR, mL/min as printed, for gout initiation; separate cancer table uses CrCl
Source date: Source revision date not established in selected retrieval.
Retrieved: 2026-09-09

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

For adult gout, the mirror's initial doses use eGFR in mL/min as printed: above 60, no modification; above 30 through 60, 50 mg daily; above 15 through 30, 50 mg every other day; 5-15, 50 mg twice weekly; below 5, 50 mg weekly. Increase by 50 mg/day at intervals of two to four weeks while monitoring kidney function and response. The source does not define a maximum dose for each eGFR band.

These are starting doses, not fixed lifetime ceilings. The source has a separate cancer-therapy table with different dosing and a dialysis row. Do not apply that row to gout or exchange eGFR and CrCl without reconciling the source method.

RDM55-rxlist-allopurinol-b04cb29148-C1 · Source locator: Dosage Modifications in Renal Impairment: adult gout Table 1; cancer-therapy Table 2

Source-specific limits

Selected sections only. A hosted mirror is not independent confirmation of the underlying label.

Source identity and provenance
Source family
product_label_mirror
Source
https://globalrph.com/rx-list/zyloprim-drug/
Retrieved
2026-09-09
Renal-function method
eGFR, mL/min as printed, for gout initiation; separate cancer table uses CrCl
Source date/version
Source revision date not established in selected retrieval.
Hash meaning
SHA-256 of local authored summary only; not original HTML, PDF or SPL bytes.
Local summary SHA-256
eccf7c10921ac600e8f772a0079e5cc303b8b1560c00b2c6ade804ded2cf40fa
Separate professional-source layer

University and professional protocols

Professional

2020 ACR gout guideline - initiation versus titrated maintenance

Open original reference

Open / share this exact local source

American College of Rheumatology / Arthritis & Rheumatology · 2020 ACR gout guideline; urate-lowering treatment selection and titration, not cancer-therapy or dialysis-specific dosing.

Renal method: CKD stage and serial serum urate; not a numerical CrCl dosing table
Source date: 2020
Retrieved: 2026-09-09

Professional guidance with defined scope. Publication date, institutional setting and source limitations remain controlling. This is not automatic preference over another source.

Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

The guideline prefers allopurinol as first-line urate-lowering therapy, including in CKD stage 3 or worse. Start low, at 100 mg/day or less and lower in CKD; a starting dose of 50 mg/day or less may be considered. Titrate with serial serum urate toward a target below 6 mg/dL rather than maintaining an arbitrary fixed dose.

Some patients with CKD may still require more than 300 mg/day to reach target. That observation does not authorize an unmonitored escalation or specify a dialysis regimen. The recommendation distinguishes safer initiation from the individualized maintenance dose.

RDM55-professional-allopurinol-309b2b661a-C1 · Source locator: Recommendations for choice of initial ULT; low starting dose; treat-to-target and serum urate target

Source-specific limits

Full primary guideline text retrieved; selected initiation and titration recommendations summarized.

This is the dated 2020 guideline, not a claim that every subsequent guideline or trial was reviewed.

Source identity and provenance
Source family
professional_guidance
Source
https://acrjournals.onlinelibrary.wiley.com/doi/10.1002/art.41247
Retrieved
2026-09-09
Renal-function method
CKD stage and serial serum urate; not a numerical CrCl dosing table
Source date/version
2020
Hash meaning
SHA-256 of local authored summary only; not original HTML, PDF or SPL bytes.
Local summary SHA-256
818b300ec6216d19af511b5022c8e60f89c1f7a3c11b173d09ee220479afd22a

Provenance and preservation

Additional summaries stored on this page: 1 official-label, 1 RX List, 1 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source
https://globalrph.com/renal/allopurinol/
Source retrieval
2026-09-05. This is not the source publication or label revision date.
Original source type
globalrph individual
Local text SHA-256
776c896469f3b6776425b80d470cb6b1a8060d694e4affc1fdc87fb798675d25
Import versus clinical validation
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

The original individual GlobalRPh pages commonly cite NIH/NLM DailyMed and instruct readers to review the applicable package insert for updates. That historical reference is preserved as context; it is not counted as an independently retrieved current label.

Read the full coverage report